Uporaba metodologije odgovornih površin za študij in situ granulacije s talinami v zvrtinčenih plasteh by SIMON KUKEC et al.
Melt granulation belongs to the group of hot-melt technologies, which represent an
alternative to the classical solvent-mediated technological processes of agglomeration.
The main advantage of hot-melt processes, including melt granulation, is the absence of
solvents, which can be efficiently utilized in enhancing chemical stability of moisture
sensitive drugs and also improving their physical properties. Moreover, a drying phase
is eliminated, which results in a more economical and environmentally friendly process.
There are also some limitations in using melt granulation processes. The major draw-
back is the required high temperature during the process, which can cause degradation
and/or oxidative instability of the ingredients, especially of thermolabile drugs (1, 2).
Equipment used for melt granulation technologies must be modified to promote
melting and prevent unwanted solidification of the product on exposed equipment sur-
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faces. Nowadays, high shear and fluid bed granulators are the most suitable equipment
for melt granulation of pharmaceutical powders (3). Interest in melt granulation in fluid
bed granulators has grown significantly since 2001, when first scientific publications on
melt granulation in fluid bed were published (4–6).
Addition of low melting binders to the starting powder mixture can be either in the
form of solid particles that melt during the process (in situ melt granulation) or in the
form of a molten liquid, optionally containing the dispersed drug (spray-on procedure).
From the industrial point of view, the melt-in procedure is favoured over the spray-on
procedure due to its avoidance of hot-melt flows (4, 7), which renders the procedure
simpler for production.
In contrast to extensive studies of wet and dry granulation processes, there is still a
lack of knowledge about the predictability and modelling of melt granulation processes
(8–10). However, the US Food and Drug Administration (FDA) Quality by Design (QbD)
initiative encourages the use of statistical tools for improving the development of high
quality pharmaceuticals (11). One of these tools is the experimental design, or design of
experiments (DoE), which allows a better understanding of how formulation and pro-
cess variables can influence product quality by defining the design space. From the ex-
perimental results of a response surface design, a polynomial model, describing the rela-
tion between a response and considered factors, is built. Afterwards, graphical and/or
statistical analysis is carried out to determine the optimal operating conditions in order
to obtain the desired formulation properties (12).
In general, once the effect of the formulation and process parameters are investi-
gated thoroughly in the laboratory scale equipment and these parameters are optimized,
the next stage is to transfer the process to the pilot scale and ultimately to the commer-
cial production scale. Batch size increase using fluid bed granulation requires a good un-
derstanding of equipment functionality and identification of the critical variables that
affect the process of agglomeration (13, 14). The majority of numerous scale-up studies
focus only on the scaling up of solvent based fluid bed granulation (15–17). However,
there is still lack of papers demonstrating the scale-up of melt granulation in a fluid bed
granulator.
The present study shows the optimization of the fluid bed melt granulation process
using a factorial design. The aim was to evaluate the influence of the formulation and
process parameters on the selected responses and to identify optimal values of indepen-
dent factors within the studied intervals. Further, the second objective of the study was
to evaluate the influence of scale-up on the optimized formulation.
EXPERIMENTAL
Materials
Carvedilol (Krka, Slovenia) (dv10 of 18.9 ìm, dv50 of 80.1 ìm, and dv90 of 190.3 ìm
measured by the laser diffraction method) was used as a poorly soluble drug, lactose 200
mesh (á-lactose monohydrate, DMV, Germany) and microcrystalline cellulose (MCC,
Avicel PH 101, FMC, Germany) were used as fillers, and poloxamer 188 powder (P188,
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Lutrol® F68, BASF, Germany) served as meltable binder. The binder sieved fraction of
particle size less than 315 ìm was used.
Preparation and optimization of granules at laboratory scale
The granules were prepared by in situ melt granulation in a laboratory scale fluid
bed granulator BX CGD 1 (Brinox process systems, Slovenia) using the process chamber
»Tornado« with a specific air distribution plate (18) and computer logging of process pa-
rameters. The batch size was 1 kg. All the ingredients, carvedilol (10 %), P188 (between
1.6 and 18.4 %), lactose and MCC at mass ratio 3:2, were placed into the process cham-
ber, and fluidized at an inlet air flow rate of 60 m3 h–1. Powders were heated at selected
inlet air temperatures between 63.2 and 96.8 °C up to the product endpoint temperature,
which was varied between 52.3 and 60.7 °C. Immediately after reaching the pre-speci-
fied product endpoint temperature, the cooling of the product was started by opening
the by-pass airway, setting the fluidizing inlet air temperature to the ambient tempera-
ture and increasing the fluidizing air flow rate to 100 m3 h–1. The process was stopped
when the product temperature reached 40 °C.
Design of experiments (DoE)
The above described granule preparation procedure was optimized by a three-fac-
tor, five-level circumscribed central composite design (CCCD), with binder content (x1),
inlet air temperature (x2), and product endpoint temperature (x3) as independent vari-
ables, as shown in Table I. The level of each independent variable was set on the basis of
preliminary screening experiments. Experimental design was carried out in two stages,
where firstly the experiments of three-factors, two-level full factorial design with tripli-
cate centre points were conducted and then supplemented with additional experiments
at a distance of ±á, i.e., 1.682 for three factors, along each axis (12). The Unscrambler®
software (version 10.1, CAMO software, Norway) was applied for generation and evalu-
ation of the statistical experimental design. All experiments were performed in random-
ized order. The mass particle diameters of d10, d50, and d90, corresponding to the 10th,
50th and 90th weight percentiles of the cumulative granulate size distribution, respecti-
vely, and D5min and D60min, corresponding to percentiles of dissolved carvedilol after 5
and 60 minutes, respectively, were selected as response variables. CCCD and the respon-
se surface methodology were used to determine the influence of a particular independ-
ent variable on selected responses. In order to find the relationship able to describe the
response variation within the design space, nonlinear quadratic models of the form gi-
ven below were constructed from a response surface design for three factors (Eq. 1):
y = â0 + â1x1 + â2x2 + â3x3 + â12x1x2 + â13x1x3 + â23x2x3 + â123x1x2x3 +
+ â11x12 + â22x22 + â33x32 1
where y is the measured response, â0 the intercept, âi the main coefficients, âij the two-
-factor interaction coefficients, âijk the three-factor interaction coefficients, and âii the
quadratic coefficients. Significant terms (p < 0.10) according to the analysis of variance
(ANOVA) were chosen for final equations. Positive and negative signs represent syner-
gistic and antagonistic effects, respectively. Response surface plots, illustrating the corre-
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lation between a fixed response variable and two factors, were also created, where the
remaining factor was fixed at the 0 level. The optimal quantity of binder and optimal
processing parameters were determined based on response surface functions according
to the desired predetermined responses.
Scale-up experiment
The granules were prepared by in situ melt granulation in a pilot scale fluid bed
granulator Aeromatic 3/2/4 (GEA Pharma Systems, Belgium) equipped with computer
logging of process parameters. The batch size was 10 kg. All the ingredients, carvedilol
(10 %), P188 (12.5 %), lactose and MCC at mass ratio 3:2, were placed into the process
chamber, fluidized at an inlet air flow rate of 180 m3 h–1 and heated at inlet air tempera-
ture of 70.0 °C to the product endpoint temperature of 56.5 °C. Immediately after reach-
ing the pre-specified product endpoint temperature, the cooling of the product was star-
ted by opening the by-pass airway, setting the fluidizing inlet air temperature to
ambient temperature and increasing the fluidizing air flow rate to 300 m3 h–1. The pro-
cess was stopped when the product temperature reached 40 °C.
Characterization of the prepared granules
Particle size, shape and flow properties. – Size distribution of the obtained granules
compared to the starting materials was determined by sieve analysis, using seven sieves
in the range 0.071–1.25 mm (Air Jet Sieve 200 LS-N, Hosokawa Alpine, Germany). Lin-
ear interpolation of the cumulative percentage frequency curve was used to determine
d50, d10, and d90. Flow properties of the obtained granules and starting materials were
evaluated by the Carr index (CI), which was determined using a Stampfvolumeter STAV
2003 (JEL Engelsmann AG, Germany) with a 250 mL glass-measuring cylinder. In order
to characterize and estimate the shape of the granules, the aspect ratio (AR) and circular-
ity (C) were calculated using a Sysmex FPIA-3000 Flow Particle Image Analyzer (Mal-
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where Fmax is the maximum Feret diameter and F90 is the Feret diameter perpendicular
to Fmax. P is the perimeter of the 2D graphical representation of granule, while A is its
surface.
Scanning electron microscopy (SEM). – Morphology of the prepared granules was ex-
amined by SEM. The samples were deposited on an adhesive double-sided carbon tape
(width 8 mm, Agar Scientific Ltd., UK). A SEM (Ultra Plus, Carl Zeiss, Germany) was
used with an acceleration voltage of 1.00 kV and a secondary electron detector.
X-ray powder diffraction (XRPD). – X-ray diffractograms were obtained using a
Philips PW3040/60X'Pert Pro MPD (Philips Electronic Instruments, USA) with Cu K0
radiation (1.5418 x 10–10 m) at 40 kV and 30 mA. The scanning angle ranged from 3.5–
32.5° of 2è; the steps were 0.04° of 2è, and the counting time was 10 s per step.
Assay. – Carvedilol content in the granulates was determined by suspending the
sample in 20 mL of methanol. Sample solution was filtered through a 0.45 µm pore filter
(Minisart RC 25, Sartorius, Germany). Drug concentration was assayed using a UV-spec-
trophotometer (Agilent 8453, Germany) at a wavelength of 285 nm. Standard solutions
used to construct the calibration curves were prepared using the same media. All analy-
ses were performed in triplicate.
Dissolution study. – In vitro dissolution studies were performed using a USP type II
apparatus (VK 7000, VanKel, U.S.A.), equipped with standard glass vessels and paddles.
Samples equivalent to 12.5 mg of carvedilol were placed in a dissolution vessel that con-
tained 900 mL of phosphate buffer solution pH 6.8 at 37 ± 0.5 °C and stirred at 50 rpm.
Samples were collected periodically, filtered through a 0.45 µm pore filter (Minisart RC
25, Sartorius, Germany) and replaced with fresh dissolution medium. Carvedilol con-
centration was determined spectrophotometrically at 285 nm (Agilent 8453, Germany).
All dissolution experiments were carried out in triplicate. Linear calibration curve was
constructed (Eq. 4) and used for analytics of dissolution samples.
y = 28.214x – 0.0058 (R2 = 0.9998) 4
Carvedilol solubility in phosphate buffer pH 6.8 for pure drug (20 g mL–1) and
granules with P188 to drug ratio 1:3 (89 g mL–1) was reported (19). Data indicate that
moderate excess solubilizing capacity of the dissolution medium was achieved for pure
drug. Drug solubilizing capacity further increased with the increase of P188 content in
prepared granule samples. Although no true sink conditions were assured over the sam-
ples, the authors think that this has somewhat assured discriminatory power of the dis-
solution method and at least limited physiological relevance (19, 20).
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RESULTS AND DISCUSSION
Optimization of melt granulation – DoE analysis
The CCCD design independent levels and the observed responses for 17 experi-
ments including triplicate centre points are shown in Table II.
Model functions were calculated from the results of CCCD experiments using the
least square method. Regression coefficients for the predictive second-order polynomial
model of d10 (y1), d50 (y2), d90 (y3), D5min (y4), and D60min (y5) are shown in Table III. The
values of the coefficients (â1-3) are related to the effect of these variables on the responses
(y1–5).
ANOVA was applied to estimate the significance of the model. It can be concluded
from the p-values in Table III that the proposed models were significant (p < 0.05) and
valid for all the examined responses. In addition, the high R2 values of models (Table III)
confirm the quality of the models. This means that the found relationships were able to
describe response variation in the function of factor variations and therefore described
the design space. Three-dimensional (3D) response surface plots are presented in Fig. 1
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9 –1 –1 –1 41.3 197.1 567.3 28.9 55.9 19.4
1 1 –1 –1 100.8 444.1 847.5 48.4 92.7 9.2
6 –1 1 –1 38.3 182.3 537.3 27.7 57.1 19.2
10 1 1 –1 105.8 448.7 861.6 47.7 90.8 9.7
2 –1 –1 1 69.3 305.9 723.1 32.4 60.6 14.3
4 1 –1 1 119.3 500.8 912.6 50.3 94.1 8.3
5 –1 1 1 58.7 279.5 632.7 29.8 58.8 16.1
8 1 1 1 87.8 425.5 833.2 48.8 93.1 11.1
3 0 0 0 80.4 371.5 813.5 42.8 80.2 12.0
7 0 0 0 83.9 385.4 821.7 40.9 81.4 11.8
11 0 0 0 82.3 380.2 823.5 40.1 79.6 11.7
14 1.68 0 0 137.5 597.3 1105.9 53.3 99.7 7.5
13 –1.68 0 0 24.2 123.1 337.1 17.4 32.6 22.7
17 0 1.68 0 73.2 355.2 756.5 39.1 77.4 13.1
15 0 –1.68 0 95.0 427.9 872.3 43.9 83.9 10.7
12 0 0 1.68 84.2 384.5 801.2 41.9 81.0 12.1
16 0 0 –1.68 47.2 239.0 494.0 38.9 78.2 17.4
and 2. These types of plots show the effects of two factors on the response at a time. In
both figures, the third factor was kept at a zero level. Influence of the selected independ-
ent variables on responses, i.e., granule particle size (y1-3) and drug dissolution rate
(y4-5), is explained in detail below.
Effect of variables on the particle size of granules. – The results of regression coefficients
with p-values for the granule particle size parameters (d10, d50, and d90) presented in Ta-
ble III show that the most influential term (p < 0.01) of the response surface quadratic
model was the binder content coefficient, â1. The square factor coefficient of product
endpoint temperature, â33, is highly significant in case of the d90 value. In addition, coef-
ficients â13, â23, and â33 had a significant effect (p < 0.01) on granule particle size in case
of the d10 value, and coefficients â13, and â33 in case of the d50 value. Granule particle
size was found to be mostly influenced by the binder content, showing a positive effect
on granule growth, though the influence of a single factor was difficult to interpret ow-
ing to the substantial influence of interaction and square factors. In general, the trends
observed in Fig. 1a-b, representing the effect of binder content and inlet air temperature
or product endpoint temperature on d50, are similar also for d10 and d90 as responses. In
case of d10 and d50 response parameters significant (p < 0.01) interaction was observed
between binder content and product endpoint temperature, and in case of d90 parameter
the observed interaction was significant at p < 0.05. On the other side, the interaction be-
tween binder content and inlet air temperature was found insignificant (p > 0.05) in all
three cases. In the case of lower binder content, the granule particle size was increasing
with rising product endpoint temperature (Fig. 1b-c). However, in the case of higher
binder content the effect of the product endpoint temperature on particle size was less
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Table III. Regression coefficients with p-values for the predictive second-order polynomial models
of responses y1–5
y1 y2 y3 y4 y5
coeff. p-value coeff. p-value coeff. p-value coeff. p-value coeff. p-value
â0 82.11 – 379.4 – 818.5 – 41.25 – 80.39 –
â1 21.41 0.0003 88.09 0.0003 67.21 0.0084 8.94 0.0010 15.83 0.0001
â2 –4.21 0.0290 –9.82 0.1213 –17.01 0.2139 –0.38 0.6234 0.38 0.4726
â3 3.42 0.0489 22.67 0.0158 5.64 0.6379 1.18 0.1900 1.50 0.0483
â12 –1.61 0.0852 –3.71 0.2674 6.83 0.3669 0.20 0.6628 –0.29 0.3748
â13 –5.99 0.0025 –21.57 0.0042 –26.75 0.0254 –0,33 0.4906 –0.34 0.3094
â23 –5.52 0.0032 –11.44 0.0248 –19.31 0.0579 –0,28 0.5548 –0.26 0.4124
â123 –3.60 0.0109 –8.54 0.0521 –4.07 0.5726 0.08 0.8681 0.49 0.1760
â11 –0.23 0.6975 –7.77 0.0431 –30.86 0.0108 –2.03 0.0102 –4.99 0.0002
â22 0.92 0.1836 3.30 0.2464 1.99 0.7378 –0.96 0.6988 0.14 0.5971
â33 –5.59 0.0019 –24.90 0.0017 –56.98 0.0018 –0.24 0.5416 –0.23 0.3891
Model 0.0071 0.0057 0.0050 0.0379 0.0009
R2 = 0.9993 R2 = 0.9993 R2 = 0.9982 R2 = 0.9972 R2 = 0.9996
pronounced. These results suggest that an increase in binder content increases the pro-
portion of available softened or molten binding material during the granulation process,
as already reported in the literature (8, 21, 22). It may be hypothesized that each binder
particle once softened or molten is able to agglomerate a constant number of primary
solid particles by sticking; therefore lower binder content is evidently not sufficient for
complete agglomeration and leaves a significant proportion of un-granulated primary
particles. Considering the fine particle fraction, represented by the d10 parameter, the se-
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Fig. 1. 3D response surface plots showing the effect of: a) binder content and inlet air temperature
and b) binder content and product endpoint temperature on response d50, and the effect of: c) bin-
der content and product endpoint temperature and d) inlet air temperature and product endpoint
temperature on response d10.
cond interesting trend in Table III revealed a significant (p < 0.01) interaction between in-
let air temperature and product endpoint temperature. At lower product endpoint tem-
perature the fraction of fines was increasing with rising the inlet air temperature, as can
be seen from Fig. 1d. The effect of increased inlet air temperature on d10 is even more
pronounced at higher product endpoint temperatures. It may be assumed that the selec-
tion of inlet air temperature, at a constant air flow rate, defines the overall granulation
time to achieve the selected product endpoint temperature and thereby the total input of
heat. Low product endpoint temperature can be compensated by lower inlet air temper-
ature, and vice versa, ensuring sufficient heat input as a function of prolonged granula-
tion time and thereby avoiding an excessive fraction of fines. Combination of low inlet
air temperature and high product endpoint temperature will prolong granulation time
and reduce the fraction of fines most efficiently (Fig. 1d), but at the cost of increased en-
ergy consumption per batch.
Effect of variables on the drug dissolution rate. – According to the p-values of D5min and
D60min responses in Table III, the binder content coefficient, â1, followed by the square
factor coefficient of binder content, â11, are in both cases the most statistically significant
terms (p < 0.01) of the model. Inlet air temperature and product endpoint temperature
did not seem to have a significant influence on the drug dissolution rate. Response sur-
face plots exhibit a nearly linear relationship of binder content with inlet air (Fig. 2a-b)
and product endpoint temperature (Fig. 2c-d) in the form of almost straight lines. It is
evident from the plots (Fig. 2) that about 30 and 55 % of carvedilol was dissolved after 5
and 60 minutes, respectively, when poloxamer 188 was at the lowest level (5 %, m/m)
and the increase in percentiles of dissolved drug was almost exclusively binder content
dependent. This finding is in accord with the literature (23, 24) reporting that using a
polymeric meltable binder with surface active properties had a significant effect on the
enhancement of dissolution of poorly soluble drugs in melt granulation processes,
where an increase in binder content resulted in higher dissolution rate. On the other
hand, the dissolution behaviour was found to be practically independent of the varia-
tion of process parameters while keeping the binder content constant at the same time.
Granule flowability. – The Carr index, as an indicator of granule flowability, was cal-
culated, and the values are given in Table II. It was found that the results of granule
flowability were in direct correlation with granule particle size. As expected, larger par-
ticle size resulted in better flowability of granules, i.e., lower Carr index, as presented in
Table II. For example, for all granulates having the d50 value above 300 µm the Carr in-
dex values were within range 5–15 %, indicating good flow properties.
505
S. Kukec et al.: A study of in situ fluid bed melt granulation using response surface methodology, Acta Pharm. 62 (2012) 497–513.
Table IV. Assay in different particle size fractions
Particle size
fraction





0–250 µm 100.7  0.9 101.6  0.5
250–710 µm 99.8  0.6 99.4  0.7
710–1250 µm 97.9  0.4 99.1  0.6
Assay. – The actual drug content of carvedilol in granules was between 98.4 and
101.8 % of the theoretical drug content, with RSD values below 1 % for all obtained gra-
nules (runs 1–17 as listed in Table II), indicating uniform distribution of the drug in granu-
les. This means that the actual drug content in granules can be expected to be in accord
with the theoretical value within the design space of this study. We have also analyzed
the assay in different particle size fractions for optimal laboratory and pilot scale runs
(Table IV). Although the in situ hot melt granulation process was used for the prepara-
tion of granules, the results showed no significant dependence of the drug assay as a
function of particle size fraction.
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Fig. 2. 3D response surface plots showing the effect of binder content and inlet air temperature on
responses: a) D5min, and b) D60min and the effect of binder content and product endpoint tempera-
ture on responses c) D5min, and d) D60min.
Optimized granulation experiment
At the end, the optimal quantity of the binder and optimal processing parameters
for melt granulation were identified graphically and mathematically using a regression
model within the investigated experimental region. It was necessary to find an optimal
compromise between the values of selected factors in order to obtain a granulate with
the mass median diameter (d50) of approx. 450 µm by minimizing the amount of fines
(d10 > 100 µm) and the amount of lumps (d90 < 900 µm) at the same time, and simul-
taneously maximizing the carvedilol dissolution rate enhancement (D5min > 45 % and
D60min > 85 %). Statistically calculated values describing the optimal values of independ-
ent variables were 12.5 % for binder (P188) content, 70 °C for inlet air temperature, and
56.5 °C for product endpoint temperature.
An independent experiment, defined as optimal run, was performed in triplicate to
verify the optimal conditions identified in the CCCD experiments. The results are listed
in Table V and show good agreement between the calculated (predicted) and experimen-
tal (observed) values of the responses. Consequently, this, along with the drug content
of 99.4 % and Carr index of 9.5 %, can add further experimental verification to the valid-
ity of the established statistical models.
Solid state characterization
To characterize the solid state of carvedilol in the granules, XRPD diffractograms
were obtained for pure crystalline carvedilol, lactose, MCC, P188, granules and the cor-
responding physical mixture (Fig. 3). Diffractograms of granules (Fig. 3f-j) exhibited pre-
dominating signals for -lactose monohydrate (43–53 % in formulations) (Fig. 3b) at
12.5, 16.4, 19–20° and 20.6–21.3° of 2è. MCC (Fig. 3c) and P188 (Fig. 3d) show broad dif-
fraction lines (at 14.5–18.5°, and 23.05–26.0° of 2è) and (at 20.5°, and 24.0–25.5° of 2è), re-
spectively. Pure carvedilol was in crystalline form (Fig. 3a), as demonstrated by the sharp
and intense diffraction lines corresponding to form II of the drug (25). XRPD diffracto-
grams of the physical mixture (Fig. 3e) and granules with binder content from 1.6 to 18.4 %
(Fig. 3f-j) show the same characteristic diffraction lines (at 5.9, 14.9, 17.6, 18.4, and 24.4°
of 2è) as pure carvedilol polymorph II (Fig. 3a). It can be concluded that there was no ev-
idence of polymorph transformation during the melt granulation process. However,
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x1 12.5 % y1 102.8 µm 107.1 ± 2.1 µm +4.2 %
x2 70.0 °C y2 449.5 µm 462.8 ± 4.7 µm +2.9 %
x3 56.5 °C y3 876.3 µm 838.6 ± 7.2 µm –4.3 %
y4 87.1 % 91.8 ± 3.1 % +5.4 %
y5 45.2 % 49.1 ± 2.3 % +8.6 %
somewhat lower intensities of diffraction lines in the physical mixture and granulates
were observed and were attributed to lower drug content due to dilution of carvedilol in
the physical mixture and granules, as already observed in a previous study (19).
Scale-up of melt granulation
The influence of scale-up (10× batch size increase) on the optimized granule compo-
sition produced at laboratory scale, as determined by CCCD, was investigated using a
pilot scale fluid bed granulator. Overall, the goal of this scale-up study was to maintain
similar product characteristics, i.e., granule particle size distribution, granule shape and
morphology, drug particle properties, content and dissolution rate as obtained for sam-
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Fig. 4. Comparison of in-line product temperature data of the optimal run – lab scale (dashed line)
and the optimal run – pilot scale (solid line).
Fig. 3. XRPD data of a) crystalline carvedilol, b) lactose, c) MCC, d) P188, e) physical mixture and
granules of f) run 13, g) run 14, h) center point, i) optimal point and j) optimal point – scale-up.
ples produced by an optimal run at laboratory scale. Therefore, the study was primarily
focused on being able to reproduce product attributes across scales. Inlet air tempera-
ture, granulation/cooling endpoint temperature, and inlet air flow rate were selected as
key scale-up process parameters. Initially, preliminary placebo trials were performed to
adjust the inlet air flow rate enabling comparable product temperature vs. time evolu-
tion as in the lab-scale optimal run while maintaining constant predetermined optimal
values for inlet air temperature of 70 °C and for product granulation/cooling endpoint
temperature of 56.5/40 °C. Fig. 4 proves that comparable production times and product
temperature profiles during the granulation procedure scale-up have been ensured. As
can be seen from experimental methods, a threefold increase in the inlet air flow rate
was used during scale-up. This can be partially attributed to the distribution-plate area
ratio between the pilot and laboratory granulators (2.65:1), as well as to the differences
in design features of both distribution plates and in equipment heat losses.
Table VI compares the technological properties for pilot scale granules to those of
the optimal laboratory run. The results of granule properties, i.e., particle size, shape,
and flowability, obtained in the pilot scale experiment are relatively close to those ob-
tained at the laboratory scale, and therefore confirm that the used process parameters
were suitably determined. In addition, SEM micrographs of granules of the optimal run
(Fig. 5a) and its scale-up run (Fig. 5b) were utilized to compare their shape and surface
morphology characteristics. It is evident that a comparable, relatively spherical and qui-
te porous granule structure was obtained in both cases. Moreover, micrographs of the
cross section of granules from both runs (Fig. 5c-d) revealed the presence of a hollow
core, indicating that immersion and layering were the dominant agglomeration mecha-
nism in both cases (4, 21).
The in vitro dissolution profiles of optimal run granules obtained at laboratory and
pilot scales compared to that of pure drug and the corresponding physical mixture are
summarized in Fig. 6. The dissolution rate of pure carvedilol was relatively low, with
the amount of drug dissolved in 60 min being less than 20 %. Comparison of dissolution
profiles of carvedilol granules produced in laboratory and pilot scale granulators indi-
cated that the dissolution behaviour was not influenced by scaling up. The in vitro disso-
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Table VI. The effect of scale up on technological properties of prepared granules
Fluid bed granulator
Laboratory scale
(batch size: 1 kg)
Pilot scale
(batch size: 10 kg)
d10 107.1 µm 98.5 µm
d50 462.8 µm 440.7 µm
d90 818.6 µm 783.0 µm
AR 0.85 ± 0.07 0.80 ± 0.08
C 0.81 ± 0.03 0.77 ± 0.05
CI 9.5 % 10.4 %
lution rate of prepared granules was significantly higher compared to pure drug and the
corresponding physical mixture. The results have confirmed that melt granulation using
hydrophilic binders, e.g., poloxamer 188 in this study, is an effective method to improve
the dissolution rate of a poorly soluble drug, e.g., carvedilol in this study. Furthermore,
XRPD analysis of the optimal run (Fig. 3f) and optimal run-scale up (Fig. 3g) granules
indicated a similar diffraction pattern with comparable intensity of the lines, thereby
suggesting that scaling up does not show any influence on the crystalline form of car-
vedilol.
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Fig. 5. SEM micrographs of granules of a) optimal run – lab scale and b) optimal run – pilot scale;
cross section of a granule of c) optimal run – lab scale and d) optimal run – pilot scale. Magnifica-
tion of 50× (a–b) and 500× (c–d).
Fig. 6. Dissolution profiles in
buffer at pH 6.8 for powders
of pure carvediol: , physical
mixture: , granules of opti-
mal run – lab scale:  and
granules of optimal run – pi-
lot scale: .
CONCLUSIONS
This study has demonstrated that response surface methodology is an appropriate
statistical method to optimize the fluid bed melt granulation process. CCCD was imple-
mented to investigate the effect of binder content, inlet air temperature, and product
endpoint temperature on the obtained granule particle size and drug dissolution rate of
a poorly soluble drug. Granule particle size was primarily dependent on binder content
but also seemed to be affected by the selected process parameters. Drug dissolution rate
was significantly influenced by the binder content, while the variation of process param-
eters did not seem to have a significant influence. An optimization study was employed
to identify the optimal quantity of the binder and optimal processing parameters that
would allow optimal selected response values to be obtained. Predictability was proven
successful, demonstrating the importance and worth of the mathematical model to sim-
plify and increase flexibility in melt granulation. Scale-up of the optimized formulation
from a lab to a pilot scale apparatus was successfully performed. The pilot scale experi-
ment resulted in final product properties close to the ones obtained during the optimi-
zed run at lab scale.
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P O V Z E T E K
Uporaba metodologije odgovornih povr{in za {tudij in situ granulacije
s talinami v zvrtin~enih plasteh
SIMON KUKEC, FRANC VRE^ER in ROK DREU
V raziskovalnem delu smo z uporabo tri-faktorskega pet-nivojskega sredi{~nega
me{anega eksperimentalnega na~rta prou~evali vpliv izbranih procesnih spremenljivk
(dele` veziva, temperatura vhodnega zraka in kon~na temperatura produkta) in situ gra-
nulacije s talinami na porazdelitev velikosti izdelanih granul in na dele` raztopljenega
karvedilola. Ugotovili smo, da pove~ana koli~ina veziva v formulaciji ka`e u~inek pove-
~anja velikosti izdelanih granul kakor tudi hitrosti raztapljanja karvedilola. Prav tako
smo ugotovili, da temperatura vhodnega zraka in kon~na temperatura produkta izka-
zujeta izrazit vpliv na parametre velikosti granul. Z metodo odgovornih povr{in smo
znotraj prou~evanih intervalov dolo~ili in validirali optimalno koli~ino veziva in opti-
malne procesne parametre. Z uporabo optimalnih formulacijskih in procesnih parame-
trov smo tehnologijo in situ granulacije s talinami uspe{no prenesli iz laboratorijskega v
ve~je (pilotno) merilo, pri ~emer smo zagotovili primerljivost prou~evanih lastnosti gra-
nulata.
Klju~ne besede: granulacija s talinami v zvrtin~enih plasteh, karvedilol, sredi{~ni me{ani na~rt, pre-
nos v ve~je merilo
Krka, d.d., Novo mesto, Slovenija
Univerza v Ljubljani, Fakulteta za farmacijo, Ljubljana, Slovenija
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